CSL said it expects to supply 30 million doses of a vaccine being developed by AstraZeneca and Oxford University to the Australian government if trials prove successful, with the first doses to be available in early 2021. CSL is trading at a multiple of 41 times its twelve-month forward earnings, against the industry average of 14, according to Refinitiv data. AstraZeneca's vaccine, which is in late-stage development, is seen as a frontrunner in the global race to deliver an effective vaccine to combat the virus. The CSL vaccine is currently in Phase 1 clinical trials to assess its safety. CSL expects to take over the Phase 2 and 3 stages in late 2020, if the drug passes Phase 1.

Source: Dhaka Tribune September 07, 2020 02:48 UTC